Cardiogenesis Corp – Contract (March 29th, 2007)

Exhibit 10.14 SETTLEMENT AGREEMENT AND GENERAL RELEASE This Confidential Settlement Agreement and General Release ("Agreement") is entered into as of this 24th day of October, 2006, by and between Michael J. Quinn ("Quinn") and Cardiogenesis Corporation (the "Company") (Quinn and the Company are collectively referred to herein as the "Parties"). This Agreement is made with reference to the following facts: WHEREAS, Quinn has made claims against the Company which include allegations of breach of employment contract and wrongful termination. WHEREAS, the Company denies that it has injured or damaged Quinn in any manner whatsoever, and denies any liability whatsoever with respect to Quinn. WHEREAS, the Parties desire to compromise and finally settle and resolve all controversies between them including, but not limited to, claims and disputes arising out of Q

Cardiogenesis Corp – Contract (August 21st, 2006)

Exhibit 10.19 [CARDIOGENESIS LOGO] CONFIDENTIALITY AND INTELLECTUAL PROPERTY AGREEMENT Cardiogenesis (the "Company") is dedicated to a policy of exerting a significant influence in its chosen fields through technical innovation and creative administration and marketing. The competitive success of this policy depends to a large extent on the Company's ability to capitalize on the creative talents of its employees and to maintain a free flow of pertinent information among its employees. For this reason, all employees are requested to sign the following Agreement under which: (I) Requirements are specified for avoiding conflicting outside activities while the employee is associated with the Company as an employee, (II) The Company is assured of disclosure of an exclusive rights to ideas, works and inventions which relate to Company business, (III) The

Cardiogenesis Corp – Amendment No. 2 to Employment Agreement Dated September 27, 2001 Between Cardiogenesis Corporation as Company and Michael J. Quinn as Executive (March 31st, 2005)

The terms and conditions of the Employment Agreement are hereby modified and amended as follows. Unless specifically defined in this Agreement, capitalized terms used herein shall have the meanings ascribed to them in the Employment Agreement.

Cardiogenesis Corp – Contract (January 26th, 2004)

EXHIBIT 4.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of January 21, 2004, by and among CardioGenesis Corporation, a California corporation (the "Company"), and the investors signatory hereto (each a "Purchaser" and collectively, the "Purchasers"). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof among the Company and the Purchasers (the "Purchase Agreement"). The Company and the Purchasers hereby agree as follows: 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: "Effectiveness Date" means, with respect to the Registration Statement required to be fi

Cardiogenesis Corp – Contract (January 26th, 2004)

EXHIBIT 4.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of January 21, 2004, by and among CardioGenesis Corporation, a California corporation (the "Company"), and each of the purchasers identified on the signature pages hereto (each a "Purchaser" and collectively the "Purchasers"). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act (as defined below), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company in the aggregate, shares of Common Stock and Warrants to purchase shares of Common Stock as set forth herein. The maximum aggregate of Subscription Amounts which the Company will accept is $2,700,000. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, an